Clinigen shares surged on Thursday after the company confirmed it has received a non-binding indicative proposal from investment firm Triton about a possible offer.
Responding to press speculation, the AIM-listed pharmaceuticals services and products company said it was in advanced talks regarding the proposal and advised shareholders to take no action.
“There can be no certainty that any firm offer will be made for the company, nor as to the terms on which any firm offer might be made,” it said.
At 1320 GMT, the shares were up 17.1% at 738.50p.
